Navigation Links
Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
Date:2/3/2009

SAN FRANCISCO, Feb. 3 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc., (Nasdaq: NLTX), announced today that Peter Strumph, Chief Executive Officer, will present a corporate overview at the 11th Annual BIO CEO & Investor Conference in New York. The presentation will take place at 3:15 p.m. ET on Monday, February 9 in the Park room at the Waldorf Astoria Hotel.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
3. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
4. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
5. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
6. Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer
7. Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
8. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
9. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
10. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
11. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: ... networking and recognition opportunities as well as advocacy for the state and region‘s ... on February 23. The Council's Innovation Forecast event highlights innovation throughout the ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... the La Gorce Country Club in Miami Beach to host its Swirl: Miami ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: